Irvine-based Allergan is reporting this morning that it has won a patent infringement case against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd., Apotex, Inc. and Apotex Corp. in the US District Court for the District of Delaware. Allergan said the defendants were looking to make generic versions of its ALPHAGAN P drug. Allergan said the court has ruled that all five patents owned by Allergan are valid and enforceable. The win means that those firms will have to wait until 2022 for approval of their generic products. Allergan's ALPHAGAN P is used for lowering elevated intraocular pressure for patients with glaucoma and ocular hypertension.